News | 12 September 2012
Prana Biotechnology (ASX: PBT, NASDAQ: PRAN) has received a recommendation from the Data Safety Monitoring Board that its clinical trial of PBT2 to treat Alzheimer's disease continue as planned following an initial review of clinical data. The 12-month ...
Click on the link to read the full article at Proactive Investors Australia
(This link will open in a new window)